The Ethics of Fecal Microbiota Transplant as a Tool for Antimicrobial Stewardship Programs

Abstract

Multidrug resistant organisms (MDROs) are a public health threat that have reduced the effectiveness of many available antibiotics. Antimicrobial stewardship programs (ASPs) have been tasked with reducing antibiotic use and therefore the emergence of MDROs. While fecal microbiota transplant (FMT) has been proposed as therapy to reduce patient colonization of MDROs, this will require additional evidence to support an expansion of the current clinical indication for FMT. This article discusses the evidence and ethics of the expanded utilization of FMT by ASPs for reasons other than severe recurrent or refractory Clostridioides (formerly Clostridium) difficile infection.

Get full access to this article

View all access options for this article.

References

Lobanovska and

Pilla , “Penicillin's Discovery and Antibiotic Resistance: Lessons for the Future?” Yale Journal of Biology and Medicine 90, no. 1 (2017): 135-145.

Id.

Levy and Marshall, supra note 1; Lobanovska and Pilla, supra note 1;

C.L.

Ventola

, “The Antibiotic Resistance Crisis. Part 1: Causes and Threats,” P&T 40, no. 4 (2015): 277-283.

Sonnevend ,

Ghazawi ,

Hashmey ,

Haidermota ,

Girgis ,

Alfaresi ,

Omar ,

D. L.

Paterson ,

H. M

Zowawi , and

Pal , “Multihospital Occur-rence of Pan-Resistant Klebsiella pneumoniae Sequence Type 147 with an ISEcp1-Directed blaOXA-181 Insertion in the mgrB Gene in the United Arab Emirates,” Antimicrob Agents Chemother 61, no. 7 (2017): e00418-17, available at <https://doi.org/10.1128/AAC.00418-17> (last visited September 24, 2019).

A. Y.

Guh ,

S. N.

Bulens ,

Mu ,

J. T.

Jacob ,

Reno ,

Scott ,

L. E.

Wilson ,

Vaeth ,

Lynfield ,

K. M.

Shaw ,

P. M.

Vagnone ,

W. M.

Bamberg ,

S. J.

Janelle ,

Dumyati ,

Concannon ,

Beldavs ,

Cunningham ,

P. M.

Cassidy ,

E. C.

Phipps ,

Kenslow ,

Travis ,

Lonsway ,

J. K.

Rasheed ,

B. M.

Limbago , and

A. J.

Kallen , “Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013,” JAMA 314, no. 14 (2015): 1479-1487, available at <https://doi.org/10.1001/jama.2015.12480> (last visited September 24, 2019).

World Health Organization, “Antimicrobial resistance Global Report on surveillance,” available at <https://www.who.int/drugresistance/documents/surveillancereport/en/> (last visited September 24, 2019).

T.H.

Dellit ,

R.C.

Owens ,

J.E.

McGowan Jr ,

D.N.

Gerding ,

R.A.

Weinstein ,

J.P.

Burke ,

Huskins ,

D.L.

Peterson ,

N.O.

Fish-man ,

C.F.

Carpenter ,

P.J.

Brennan ,

Billeter , and

T.M.

Hooton , “Infectious Disease Society of America and the Society for Healthcar Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stew-ardship,” Clinical Infectious Diseases 44, no. 2 (2007): 159-177.

CDC, “Core Elements of Antimicrobial Stewardship Programs,” 2014, available at <https://www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html> (last visited September 24, 2019).

Dellit et al., supra note 7.

10.

Id.

11.

Dellit et al., supra note 7;

K.D.

Leuthner and

G. V.

Doern , “Antimicrobial Stewardship Programs,” Journal of Clinical Microbiology 51, no. 12 (2013): 3916-3920, available at <https://doi.org/10.1128/JCM.01751-13> (last visited September 24, 2019).

12.

Leuthner and Doern, supra note 11; Dellit et al., supra note 7.

13.

Dellit et al., supra note 7; Leuthner and Doern, supra note 11.

14.

Medicare and Medicaid Programs, Hospital and Critical Access Hospital (CAH) Changes To Promote Innovation, Flexibility, and Improvement in Patient Care, 81 Fed. Reg. 39,448, 39,454-39,459 (proposed June 16, 2016).

15.

Medicare and Medicaid Programs; Reform of Requirements for Long-Term Care Facilities, 81 Fed. Reg. 68,688 (Oct. 4, 2016) (to be codified at 42 C.F.R. pt. 483); 42 C.F.R. § 483.80(a)(3) (2018).

16.

Medicare and Medicaid Programs; Reform of Requirements for Long-Term Care Facilities, 80 Fed. Reg. 42,167, 42,215 (proposed Jul. 16, 2015) (to be codified at 42 C.F.R. pt. 483).

17.

Medicare and Medicaid Programs; Reform of Requirements for Long-Term Care Facilities, 81 Fed. Reg. 68,688, 68,808 (Oct. 4, 2016).

18.

Medicare and Medicaid Programs; Reform of Requirements for Long-Term Care Facilities, 81 Fed. Reg. 68,688, 68,808 (Oct. 4, 2016).

19.

Joint Commission, “Approved: New Antimicrobial Steward-ship Standard,” Joint Commission Perspectives 36, no. 7 (2016): 1-4, available at <https://www.jointcommission.org/assets/1/6/New_Antimicrobial_Stewardship_Standard.pdf> (last visited September 24, 2019).

20.

Wei

, State Recognition, Joint Commission Website, available at <https://www.jointcommission.org/state_recognition/state_recognition.aspx> (last visited April 15, 2019).

21.

Facts About Federal Deemed Status and State Recognition, Joint Commission Website, available at <https://www.joint-commission.org/facts_about_federal_deemed_status_and_state_recognition/> (last visited April 15, 2019).

22.

Hyun

, “Delays Hinder Effort to Protect Medicare, Medicaid Patients From Superbugs,” Pew Charitable Trusts, November 9, 2018, available at <https://www.pewtrusts.org/en/research-and-analysis/articles/2018/11/09/delays-hinder-effort-to-protect-medicare-medicaid-patients-from-superbugs> (last visited September 24, 2019).

23.

24.

Medicare and Medicaid Programs, Hospital and Critical Access Hospital (CAH) Changes To Promote Innovation, Flexibility, and Improvement in Patient Care; Extension of Time-line for Publication of the Final Rule, 84 Fed. Reg. 27,069 (June 11, 2019).

25.

P.K.

Tosh and

L.C.

McDonald , “Infection Control in the Multidrug-Resistant Era: Tending the Human Microbiome,” Clinical Infectious Diseases 54, no. 4 (2012): 707-713.

26.

M.M. Pettigrew et al., supra note 25, Tosh and McDonald, supra note 25.

27.

B.H.

Mullish ,

M. N

Quraishi ,

J. P

Segal ,

V. L

McCune ,

Baxter ,

G. L

Marsden ,

D. J

Moore ,

Colville ,

Bhala ,

T. H

Iqbal ,

Settle ,

Kontkowski ,

A. L

Hart ,

P. M

Hawkey ,

S. D

Goldenberg , and

H. R. T.

Williams , “The Use of Faecal Microbiota Transplant as Treatment for Recurrent or Refractory Clostridium Difficile Infection and Other Potential Indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) Guidelines,” Gut 67, no. 11 (2018): 1920-1941, available at <https://doi.org/10.1136/gutjnl-2018-316818> (last visited September 24, 2019).

28.

Martin ,

Muñoz ,

Yoder ,

J. R

Allegretti ,

Smith , and

Kassam , “Sa1093 Assessing the Landscape of Fecal Micro-biota Transplantation Programs for Recurrent Clostridium difficile Infection: A Survey of Existing Practices Among Healthcare Centers Using an International Public Stool Bank,” Gastroenterology 150, no. 4 (2016): S238, available at <https://doi.org/10.1016/s0016-5085(16)30866-6> (last visited September 24, 2019).

29.

Shogbesan ,

D. R

Poudel ,

Victor ,

Jehangir ,

Fadahunsi ,

Shogbesan , and

Donato , “A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised Patients,” Canadian Journal of Gastroenterology and Hepatology (2018): 1394379, available at <https://doi.org/10.1155/2018/1394379> (last visited September 24, 2019).

30.

Shogbesan, supra note 29.

31.

Shogbesan, supra note 29; van Nood et al., supra note 29.

32.

Mullish, supra note 27.

33.

D.T.

Grima ,

G. F

Webb , and

E. M

D'Agata , “Mathematical Model of the Impact of a Nonantibiotic Treatment for Clostridium difficile on the Endemic Prevalence of Vancomycin-Resistant Enterococci in a Hospital Setting,” Computational and Mathematical Methods in Medicine (2012): 605861, availkable at <https://doi.org/10.1155/2012/605861> (last visited September 24, 2019).

34.

Lahtinen

et al., “Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidi-ties as well as in patients with new indications: A case series,” World Journal Gastroenterology 23, no. 39: 7174-7184.

35.

M. J

Vehres-child

et al., “A Multicentre Cohort Study on Colonization and Infection with ESBL-Producing Enterobacteriaceae in High-Risk Patients with Haematological Malignancies,” Journal of Antimicrobial Chemotherapy 69, no. 12 (2014): 3387-3392, available at <https://doi.org/10.1093/jac/dku305> (last visited September 24, 2019).

36.

Tacconelli ,

Mazzaferri ,

A. M

de Smet ,

Bragantini ,

Eggimann ,

B. D

Huttner ,

E. J

Kuijper ,

J. C

Lucet ,

N. T

Mutters ,

Sanguinetti ,

M. J

Schwaber ,

Souli ,

Torre-Cisneros ,

J. R

Price , and

Rodriguez-Bano , “ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers,” Clinical Microbiology and Infection (2019), available at <https://doi.org/10.1016/j.cmi.2019.01.005> (last visited September 24, 2019); Vehres-child et al., supra note 35.

37.

J.I.

Barrasa-Villar

et al., “Impact on Morbidity, Mortality, and Length of Stay of Hospital-Acquired Infections by Resistant Microorganisms,” Clinical Infectious Diseases 65, no. 4 (2017): 644-652, available at <https://doi.org/10.1093/cid/cix411> (last visited September 25, 2019).

38.

Millan

et al., “Fecal Microbial Transplants Reduce Antibiotic-Resistant Genes in Patients With Recurrent Clostridium difficile Infection,” Clinical Infectious Diseases 62, no. 12 (2016): 1479-1486, available at <https://doi.org/10.1093/cid/ciw185> (last visited September 25, 2019).

39.

Id.

40.

Baxter and

Colville , “Adverse Events in Faecal Microbiota Transplant: A Review of the Literature,” Journal of Hospital Infection 92, no. 2 (2016): 117-127, available at <https://doi.org/10.1016/j.jhin.2015.10.024> (last visited September 26, 2019).

41.

M. H

Woodworth

et al., “Ethical Considerations in Microbial Therapeutic Clinical Trials,” The New Bioethics 23, no. 3 (2017): 210-218, available at <https://doi.org/10.1080/20502877.2017.1387386> (last visited September 26, 2019).

42.

Leung ,

Vincent ,

T. J

Edens ,

Miller , and

A. R

Manges , “Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection,” Clinical Infectious Diseases 66, no. 3 (2018): 456-457, available at <https://doi.org/10.1093/cid/cix821> (last visited September 26, 2019).

43.

Mullish, supra note 27.

44.

U.S. Food & Drug Admin., Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms, June 13, 2019, available at <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiotatransplantation-and-risk-serious-adverse> (last visited September 26, 2019).

45.

Ma, supra note 41; Rhodes, supra note 41.

46.

J. F

Childress and

T. L

Beauchamp , Principles of Biomedical Ethics. 7th ed. (New York, NY: Oxford University Press, 2013).

47.

A. R

Jonsen ,

Siegler , and

W. J

Winslade , Clinical Ethics: A Practical Approach to Ethical Decisions in Clinical Medicine 8th ed. (McGraw-Hill Education, 2015).

48.

Ma ,

Liu ,

Rhodes ,

Nie , and

Zhang , “Ethical Issues in Fecal Microbiota Transplantation in Practice,” American Journal of Bioethics 17, no. 5 (2017): 34-45, available at <https://doi.org/10.1080/15265161.2017.1299240> (last visited September 26, 2019); Rhodes, supra note 41.

49.

Tacconelli

et al., “ESCMID-EUCIC Clinical Guidelines on Decolonization of Multidrug-Resistant Gram-Negative Bacteria Carriers,” Clinical Microbiology and Infection 25, no. 7 (2019), available at <https://doi.org/10.1016/j.cmi.2019.01.005> (last visited September 26, 2019).

50.

M.J. Vehreschild et al., supra note 35.

51.

M. Laffin, supra note 35.

52.

Davido ,

Batista ,

Michelon ,

Lepainteur ,

Bouchand ,

Lepeule ,

Salomon ,

Vittecoq ,

Duran ,

Escaut ,

Sobhani ,

Paul ,

Lawrence ,

Perronne ,

Chast , and

Dinh , “Is Faecal Microbiota Transplantation an Option to Eradicate Highly Drug-Resistant Enteric Bacteria Carriage?” Journal of Hospital Infection 95, no. 4 (2017): 433-437, available at <https://www.ncbi.nlm.nih.gov/pubmed/28237504> (last visited December 5, 2019).

53.

Id.

54.

Bilinski

et al., “Fecal Microbiota Transplantation in Patients With Blood Disorders Inhibits Gut Colonization With Antibiotic-Resistant Bacteria: Results of a Prospective, Single-Center Study,” Clinical Infectious Diseases 65, no. 3 (2017): 364-370, available at <https://doi.org/10.1093/cid/cix252> (last visited September 26, 2019).

55.

Davido, supra note 52; Bilinski, supra note 54.

56.

clinicaltrials.gov, (search terms “fecal microbiota,” “MDRO” and “Fecal Transplantation for primary Clostridium infection”), (last visited April 15, 2019).

57.

Mullish, supra note 27; U.S. Food & Drug Admin., supra note 44.

58.

Rolston

, “Infections in Cancer Patients with Solid Tumors: A Review,” Infectious Diseases and Therapies 6, no. 1 (2017): 69-83, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336421/> (last visited September 26, 2019).

59.

Shogbesan, supra note 29;

B.J.

Webb ,

Brunner ,

C. D

Ford ,

M. A

Gazdik ,

F. B

Petersen , and

Hoda , “Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Hematopoietic Stem Sell Transplant Recipients,” Transplant Infectious Disease 18, no. 4 (2016): 628-633, available at <https://doi.org/10.1111/tid.12550> (last visited September 26, 2019).

60.

C.R.

Kelly

et al., “Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients,” American Journal of Gastroenterology 109, no. 7 (2014): 1065-1071, available at <https://doi.org/10.1038/ajg.2014.133> (last visited September 26, 2019).

61.

Y. W

Cheng

et al., “Fecal Microbiota transplantation for the Treatment of Recurrent and Severe Clostridium difficile Infection in Solid Organ Transplant Recipients: A Multi-center Experience,” American Journal of Transplantation 19, no. 2 (2019): 501-511, available at <https://doi.org/10.1111/ajt.15058> (last visited September 26, 2019).

62.

Id.

63.

Friedman-Korn

et al., “Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients,” Digestive Diseases and Sciences 63, no. 1 (2018): 198-203, available at <https://doi.org/10.1007/s10620-017-4833-2> (last visited September 26, 2019).

64.

El-Saifi ,

Moyle , and

Jones , “Medication Adherence in Older Patients with Dementia: A Systematic Literature Review,” Journal of Pharmacy Practice 31, no. 3 (2017): 322-334, available at <https://doi.org/10.1177/0897190017710524> (last visited September 27, 2019).

65.

K.L.

Bunnell ,

L. H

Danziger , and

Johnson , “Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin,” Open Forum Infectious Diseases 4, no. 2 (2017): ofx078, available at <https://doi.org/10.1093/ofid/ofx078> (last visited September 27, 2019).

66.

Id.

67.

R. U

Varier ,

Biltaji ,

K. J

Smith ,

M. S

Roberts ,

M. K

Jensen ,

LaFleur , and

R. E

Nelson , “Cost-Effectiveness Analysis of Treatment Strategies for Initial Clostridium difficile Infection,” Clinical Microbiology and Infection 20, no. 12 (2014): 1343-1351, available at <https://doi.org/10.1111/1469-0691.12805> (last visited September 27, 2019).

68.

Id.

69.

Denton ,

Topping , and

Humphreys , “Managing Clostridium difficile Infection in Hospitalised Patients,” Nursing Standard 28, no. 33 (2014): 37-43, available at <https://doi.org/10.7748/ns2014.04.28.33.37.e8461> (last visited September 27, 2019).

70.

F. E

Juul

et al., “Fecal Microbiota Transplantation for Primary Clostridium difficile Infection,” New England Journal of Medicine 378, no. 26 (2018): 2535-2536, available at <https://doi.org/10.1056/NEJMc1803103> (last visited September 27, 2019).

71.

Id.

72.

Clinicaltrials.gov, supra note 56.

73.

Brody

, “Shared Decision Making and Determining Decision-Making Capacity,” Primary Care: Clinics in Office Practice 32, no. 3 (2005): 645-658, available at <https://doi.org/10.1016/j.pop.2005.06.004> (last visited September 27, 2019).

74.

S.A.

Kahn ,

Vachon ,

Rodriquez ,

S. R

Goeppiger ,

Surma ,

Marks , and

D. T

Rubin , “Patient Perceptions of Fecal Microbiota Transplantation for Ulcerative Colitis,” Inflammatory Bowel Diseases 19, no. 7 (2013): 1506-1513, available at <https://doi.org/10.1097/MIB.0b013e318281f520> (last visited December 6, 2019).

75.

Park ,

Mone ,

J. C

Price ,

Tzimas ,

Hirsh ,

M. A

Poles ,

Malter , and

L. A

Chen , “Perceptions of Fecal Microbiota Transplantation for Clostridium difficile Infection: Factors that Predict Acceptance,” Annals of Gastroenterology 30, no. 1 (2017): 83-88, available at <https://doi.org/10.20524/aog.2016.0098> (last visited September 27, 2019).

76.

Ma, supra note 48; Rhodes, supra note 41.

77.

Unguru

, “Pediatric decision-making: informed consent, parental permission, and child assent,” in Clinical Ethics in Pediatrics: A Case-Based Textbook, edited by

D. S

Diekema

et al. (Cambridge University Press, 2011): 1-6.

78.

Kahn ,

Nicholson and

Gulati , “Use of FMT in the pediatric population: Safety, Efficacy and Ethical issues for the practitioner,” previously presented during the working group for this symposium.

79.

H. Brody, supra note 73.

80.

Bean

, “Navigating the Murky Intersection Between Clinical and Organizational Ethics: A Hybrid Case Taxonomy,” Bioethics 25, no. 6 (2011): 320-325, available at <https://doi.org/10.1111/j.1467-8519.2009.01783.x> (last visited September 27, 2019).

81.

J.L.

Gibson ,

Sibbald ,

Connolly , and

Singer , “Organizational Ethics,” in The Cambridge Textbook of Bioethics, edited by

P. A

Singer and

A. M

Viens . (Cambridge University Press, 2008).

82.

R.L.P.

Jump ,

Gaur ,

M. J

Katz ,

C. J

Crnich ,

Dumyati ,

M. S

Ashraf ,

Frentzel ,

S. J

Schweon ,

Sloane , and

Nace , “Template for an Antibiotic Stewardship Policy for Post-Acute and Long-Term Care Settings,” Journal of the American Medical Directors Association 18, no. 11 (2017): 913-920, available at <https://doi.org/10.1016/j.jamda.2017.07.018> (last visited September 27, 2019).

83.

Institute for Healthcare Improvement, “The IHI Triple Aim,” available at <http://www.ihi.org/Engage/Initiatives/TripleAim/Pages/default.aspx> (last visited September 27, 2019).

84.

P.K.

Tosh and

L.C.

McDonald , “Infection Control in the Multidrug-Resistant Era: Tending the Human Microbiome,” Clinical Infectious Diseases 54, no. 4 (2012): 707-713.

85.

K.C.

O'Doherty ,

Virani , and

E. S

Wilcox , “The Human Microbiome and Public Health: Social and Ethical Considerations,” American Journal of Public Health 106, no. 3 (2016): 414-420, available at <https://doi.org/10.2105/ajph.2015.302989> (last visited September 27, 2019).

86.

R. U

Varier ,

Biltaji ,

K. J

Smith ,

M. S

Roberts ,

Kyle Jensen ,

LaFleur , and

R. E

Nelson . “Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection,” Infection Control and Hospital Epidemiology 36, no. 4 (2015): 438-444, available at <https://doi.org/10.1017/ice.2014.80> (last visited September 27, 2019).

87.

Waye ,

Atkins , and

Kao , “Cost Averted With Timely Fecal Microbiota Transplantation in the Management of Recurrent Clostridium difficile Infection in Alberta, Canada,” Journal of Clinical Gastroenterology 50, no. 9 (2016): 747-753, available at <https://doi.org/10.1097/mcg.0000000000000494> (last visited September 27, 2019).

88.

Rhodes, supra note 41; American Gastroenterological Association, Fecal Microbiota Transplantation National Registry, available at <https://www.gastro.org/research-and-awards/registries-and-studies/fecal-microbiota-transplantation-fmt-national-registry> (last visited September 27, 2019).

89.

Kullar ,

Vassallo ,

Turkel ,

Chopra ,

K. S

Kaye , and

Dhar , “Degowning the controversies of contact precautions for methicillin-resistant Staphylococcus aureus: A review,” American Journal of Infection Control 44, no. 1 (2016): 97-103, available at <https://doi.org/10.1016/j.ajic.2015.08.003> (last visited September 27, 2019).

90.

45 C.F.R. § 46.102(l) (2018).

91.

45 C.F.R. § 46.102(e)(1)(ii) (2018).

92.

45 C.F.R. § 46.101(a) (2018).

93.

45 C.F.R. § 46.102(l) (2018).

94.

U.S. Food & Drug Admin., “Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies,” March 2016, available at <https://www.fda.gov/media/96562/download> (last visited September 27, 2019).

95.

21 C.F.R. § 312.40(a) (2018).

96.

21 C.F.R. Part 50 (2018).

97.

21 C.F.R. Part 56 (2018).

98.

Khoruts ,

D. E

Hoffmann , and

F.P.

Palumbo , “The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation,” Journal of Law, Medicine & Ethics 47, no. 4 (2019): 482-504.

99.

Supported in work by McGovern, Hecht, and Wilcox, presented during the working group for this symposium.

100.

21 C.F.R. Part 50 (2018); 21 C.F.R. § 312.40(a) (2018).

101.

U.S. Food & Drug Admin., Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms, June 13, 2019, available at <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse> (last visited September 27, 2019).

102.

Protection of Human Subjects, 45 C.F.R. part 46 (2018).

103.

S. P

Hey ,

Weijer ,

Taljaard , and

A. S

Kesselheim , “Research Ethics for Emerging Trial Designs: Does Equipoise Need to Adapt?” BMJ 360 (2018): k226, available at <https://doi.org/10.1136/bmj.k226> (last visited September 27, 2019).

104.

Jongsma ,

Bos , and

van de Vathorst . “Morally Relevant Similarities and Differences Between Children and Dementia Patients as Research Subjects: Representation in Legal Documents and Ethical Guidelines,” Bioethics 29, no. 9 (2015): 662-670, available at <https://doi.org/10.1111/bioe.12195> (last visited September 27, 2019).

105.

Id.

106.

Id.

107.

45 C.F.R. § 46.405 (2018).

108.

45 C.F.R. § 46.116 (2018).

109.

Jongsma, supra note 104.

110.

Jongsma, supra note 104.

111.

Jongsma, supra note 104.

112.

Jongsma, supra note 104.

113.

M.H.

Woodworth ,

K. L

Sitchenko ,

Carpentieri ,

R. J

Friedman-Moraco ,

Wang , and

C. S

Kraft , “Ethical Considerations in Microbial Therapeutic Clinical Trials,” The New Bioethics 23, no. 3 (2017): 210-218, available at <https://doi.org/10.1080/20502877.2017.1387386> (last visited September 27, 2019).